Suppr超能文献

血清素能致幻剂:评估作用机制的实验方法

Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.

作者信息

Canal Clinton E

机构信息

Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA, USA.

出版信息

Handb Exp Pharmacol. 2018;252:227-260. doi: 10.1007/164_2018_107.

Abstract

Recent, well-controlled - albeit small-scale - clinical trials show that serotonergic psychedelics, including psilocybin and lysergic acid diethylamide, possess great promise for treating psychiatric disorders, including treatment-resistant depression. Additionally, fresh results from a deluge of clinical neuroimaging studies are unveiling the dynamic effects of serotonergic psychedelics on functional activity within, and connectivity across, discrete neural systems. These observations have led to testable hypotheses regarding neural processing mechanisms that contribute to psychedelic effects and therapeutic benefits. Despite these advances and a plethora of preclinical and clinical observations supporting a central role for brain serotonin 5-HT receptors in producing serotonergic psychedelic effects, lingering and new questions about mechanisms abound. These chiefly pertain to molecular neuropharmacology. This chapter is devoted to illuminating and discussing such questions in the context of preclinical experimental approaches for studying mechanisms of action of serotonergic psychedelics, classic and new.

摘要

近期,尽管规模较小但控制良好的临床试验表明,包括裸盖菇素和麦角酸二乙酰胺在内的血清素能迷幻剂在治疗包括难治性抑郁症在内的精神疾病方面具有巨大潜力。此外,大量临床神经影像学研究的新结果正在揭示血清素能迷幻剂对离散神经系统内功能活动以及跨系统连接的动态影响。这些观察结果引发了关于导致迷幻效果和治疗益处的神经处理机制的可测试假设。尽管有这些进展以及大量临床前和临床观察结果支持大脑5-羟色胺(5-HT)受体在产生血清素能迷幻效果中起核心作用,但关于机制的旧问题和新问题仍然大量存在。这些问题主要涉及分子神经药理学。本章致力于在研究血清素能迷幻剂作用机制的临床前实验方法(经典方法和新方法)的背景下阐明和讨论此类问题。

相似文献

1
Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.
Handb Exp Pharmacol. 2018;252:227-260. doi: 10.1007/164_2018_107.
2
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.
Behav Brain Res. 2015 Jan 15;277:99-120. doi: 10.1016/j.bbr.2014.07.016. Epub 2014 Jul 15.
3
Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice.
Naunyn Schmiedebergs Arch Pharmacol. 2024 May;397(5):3019-3035. doi: 10.1007/s00210-023-02778-x. Epub 2023 Oct 24.
4
Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives.
Neuroimage. 2019 Oct 15;200:281-291. doi: 10.1016/j.neuroimage.2019.06.053. Epub 2019 Jun 24.
5
[Contribution of serotonin 5-HT receptor to antidepressant effect of serotonergic psychedelics].
Nihon Yakurigaku Zasshi. 2023 May 1;158(3):229-232. doi: 10.1254/fpj.22141. Epub 2023 Mar 29.
6
Psilocybin and Other Classic Psychedelics in Depression.
Curr Top Behav Neurosci. 2024;66:149-174. doi: 10.1007/7854_2023_451.
7
The promises and perils of psychedelic pharmacology for psychiatry.
Nat Rev Drug Discov. 2022 Jun;21(6):463-473. doi: 10.1038/s41573-022-00421-7. Epub 2022 Mar 17.
9
Beyond the 5-HT Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action.
J Neurosci. 2023 Nov 8;43(45):7472-7482. doi: 10.1523/JNEUROSCI.1384-23.2023.
10
Models of psychedelic drug action: modulation of cortical-subcortical circuits.
Brain. 2022 Apr 18;145(2):441-456. doi: 10.1093/brain/awab406.

引用本文的文献

3
Serotonergic psychedelic 5-MeO-DMT alters plasticity-related gene expression and generates anxiolytic effects in stressed mice.
Mol Psychiatry. 2025 Jan;30(1):50-60. doi: 10.1038/s41380-024-02655-w. Epub 2024 Jul 5.
4
Comparative Pharmacological Effects of Lisuride and Lysergic Acid Diethylamide Revisited.
ACS Pharmacol Transl Sci. 2024 Feb 5;7(3):641-653. doi: 10.1021/acsptsci.3c00192. eCollection 2024 Mar 8.
6
Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy--dimethyltryptamine in Mice.
ACS Pharmacol Transl Sci. 2023 Mar 10;6(4):567-577. doi: 10.1021/acsptsci.2c00222. eCollection 2023 Apr 14.
7
Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice.
ACS Pharmacol Transl Sci. 2022 Nov 2;5(11):1181-1196. doi: 10.1021/acsptsci.2c00177. eCollection 2022 Nov 11.
8
9
Activity of ("Kratom") Alkaloids at Serotonin Receptors.
J Med Chem. 2021 Sep 23;64(18):13510-13523. doi: 10.1021/acs.jmedchem.1c00726. Epub 2021 Sep 1.
10
The Therapeutic Potential of Psilocybin.
Molecules. 2021 May 15;26(10):2948. doi: 10.3390/molecules26102948.

本文引用的文献

1
Tutorials for Electrophysiological Recordings in Neuronal Tissue Engineering.
ACS Biomater Sci Eng. 2017 Oct 9;3(10):2235-2246. doi: 10.1021/acsbiomaterials.7b00318. Epub 2017 Aug 28.
2
5-HT Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology.
Cell. 2018 Feb 8;172(4):719-730.e14. doi: 10.1016/j.cell.2018.01.001. Epub 2018 Feb 1.
4
The importance of small polar radiometabolites in molecular neuroimaging: A PET study with [C]Cimbi-36 labeled in two positions.
J Cereb Blood Flow Metab. 2018 Apr;38(4):659-668. doi: 10.1177/0271678X17746179. Epub 2017 Dec 7.
5
Temporal Bias: Time-Encoded Dynamic GPCR Signaling.
Trends Pharmacol Sci. 2017 Dec;38(12):1110-1124. doi: 10.1016/j.tips.2017.09.004. Epub 2017 Oct 23.
6
D dopamine receptor high-resolution structures enable the discovery of selective agonists.
Science. 2017 Oct 20;358(6361):381-386. doi: 10.1126/science.aan5468.
7
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms.
Sci Rep. 2017 Oct 13;7(1):13187. doi: 10.1038/s41598-017-13282-7.
8
Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT.
Sci Rep. 2017 Oct 9;7(1):12863. doi: 10.1038/s41598-017-12779-5.
9
Fenfluramine Reduces [11C]Cimbi-36 Binding to the 5-HT2A Receptor in the Nonhuman Primate Brain.
Int J Neuropsychopharmacol. 2017 Sep 1;20(9):683-691. doi: 10.1093/ijnp/pyx051.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验